Dyadic International, Inc. (DYAI) Stock Price

DYAIStock

$0.69−20.08%52W

Market Cap$27.68M

P/E—

PEG Ratio—

Div yield—

Beta1.00

DYAI Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-27.54%

Price vs S&P 500 (4W)-38.97%

VGM Score45.08

Book Value / Share (Quarterly)$0.03

P/TBV (Annual)25.52x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)1.79%

Cash Flow / Share (Quarterly)$-0.16

Price vs S&P 500 (YTD)-39.69%

Gross Margin (TTM)26.10%

Net Profit Margin (TTM)-191.50%

EPS (TTM)$-0.23

10-Day Avg Trading Volume0.19M

EPS Excl Extra (TTM)$-0.23

Revenue Growth (5Y)14.07%

EPS (Annual)$-0.23

ROI (Annual)-117.67%

Gross Margin (Annual)24.93%

Net Profit Margin (5Y Avg)-303.18%

Cash / Share (Quarterly)$0.15

Revenue Growth QoQ (YoY)182.28%

ROA (Last FY)-74.05%

Revenue Growth TTM (YoY)7.13%

EBITD / Share (TTM)$-0.22

ROE (5Y Avg)-221.45%

Operating Margin (TTM)-186.28%

Cash Flow / Share (Annual)$-0.16

P/B Ratio23.04x

P/B Ratio (Quarterly)27.60x

Net Income / Employee (Annual)$-1,227,400

EV / Revenue (TTM)7.67x

Net Interest Coverage (TTM)-32.67x

ROA (TTM)-77.64%

EV / EBITDA (TTM)100.64x

EPS Incl Extra (Annual)$-0.23

Current Ratio (Annual)2.68x

Quick Ratio (Quarterly)2.36x

3-Month Avg Trading Volume0.27M

52-Week Price Return-20.08%

Revenue / Employee (TTM)$634,600

Tangible BV / Share (Quarterly)$0.02

P/S Ratio (Annual)9.19x

Asset Turnover (Annual)0.31x

52-Week High$1.60

Operating Margin (5Y Avg)-321.89%

EPS Excl Extra (Annual)$-0.23

Tangible BV CAGR (5Y)-31.65%

26-Week Price Return-16.29%

Quick Ratio (Annual)2.62x

13-Week Price Return-8.20%

Total Debt / Equity (Annual)4.08x

Current Ratio (Quarterly)2.42x

Enterprise Value$29.19M

Revenue / Share Growth (5Y)10.23%

Asset Turnover (TTM)0.41x

Book Value / Share Growth (5Y)-49.46%

Revenue / Employee (Annual)$515,100

Inventory Turnover (Annual)3.49x

Pretax Margin (Annual)-238.31%

Cash / Share (Annual)$0.20

3-Month Return Std Dev115.96%

Gross Margin (5Y Avg)33.88%

Net Income / Employee (TTM)$-1,215,300

ROE (Last FY)-597.58%

Net Interest Coverage (Annual)-30.85x

EPS Basic Excl Extra (Annual)$-0.23

P/FCF (TTM)19.59x

Receivables Turnover (TTM)6.25x

Total Debt / Equity (Quarterly)4.08x

EPS Incl Extra (TTM)$-0.23

Receivables Turnover (Annual)4.66x

ROI (TTM)-84.44%

P/S Ratio (TTM)7.46x

Pretax Margin (5Y Avg)-303.18%

Revenue / Share (Annual)$0.09

Tangible BV / Share (Annual)$0.06

Price vs S&P 500 (52W)-38.39%

Year-to-Date Return-27.73%

5-Day Price Return-11.10%

EPS Normalized (Annual)$-0.23

ROA (5Y Avg)-69.53%

Net Profit Margin (Annual)-238.31%

Month-to-Date Return-35.30%

EBITD / Share (Annual)$-0.22

Operating Margin (Annual)-232.75%

LT Debt / Equity (Annual)4.08x

ROI (5Y Avg)-94.03%

LT Debt / Equity (Quarterly)4.08x

EPS Basic Excl Extra (TTM)$-0.23

P/TBV (Quarterly)84.50x

P/B Ratio (Annual)27.60x

Inventory Turnover (TTM)0.51x

Pretax Margin (TTM)-191.50%

Book Value / Share (Annual)$0.03

Price vs S&P 500 (13W)-11.00%

Beta1.00x

P/FCF (Annual)6.06x

Revenue / Share (TTM)$0.10

ROE (TTM)-350.86%

52-Week Low$0.65

vGradeD

gGradeB

mGradeD

vgmGradeC

DYAI Earnings Surprise History

Q2 25-0.06est. -0.06

Q3 25-0.06est. -0.04

Q4 25-0.06est. -0.04

Q1 26-0.05est. -0.04

Q2 26-0.06est. -0.04

DYAI Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.14

Industry Peers — Biological Products(183)

Symbol	Value Score	Growth Score	Momentum Score	Price
DYAIDyadic International, Inc.	D	B	D	$0.69
AMGNAmgen Inc	C	C	B	$442.24
GILDGilead Sciences Inc	C	B	B	$148.77
MRNAModerna, Inc. Common Stock	D	C	A	$158.83
ARGXargenx SE American Depositary Shares	D	A	B	$1019.49
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$211.38
BIIBBiogen Inc. Common Stock	C	D	B	$220.77
BNTXBioNTech SE American Depositary Share	C	C	B	$114.05
NBIXNeurocrine Biosciences Inc	C	B	C	$153.37
EXELExelixis Inc	C	B	B	$56.72
HALOHalozyme Therapeutics, Inc.	C	B	A	$109.32
TECHBio-Techne Corp.	D	C	B	$72.33
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	$356.19
KYMRKymera Therapeutics, Inc. Common Stock	D	B	B	$126.64
RGENRepligen Corp	D	C	A	$181.69
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	$134.85
TWSTTwist Bioscience Corporation Common Stock	D	B	A	$151.42
PCVXVaxcyte, Inc. Common Stock	—	—	B	$61.09
QGENQIAGEN N.V.	C	C	C	$43.65
IMVTImmunovant, Inc. Common Stock	—	—	B	$43.50
IBRXImmunityBio, Inc. Common Stock	F	A	C	$8.19
SRRKScholar Rock Holding Corporation Common Stock	F	—	B	$58.25
CGONCG Oncology, Inc. Common stock	F	A	A	$78.95
CRSPCRISPR Therapeutics AG	D	B	B	$60.90
RLAYRelay Therapeutics, Inc. Common Stock	F	D	A	$20.57
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	A	$26.25
DNLIDenali Therapeutics Inc. Common Stock	F	—	B	$24.93
IOVAIovance Biotherapeutics, Inc. Common Stock	C	B	A	$8.44
BEAMBeam Therapeutics Inc. Common Stock	C	B	B	$31.03
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	$71.45
BCRXBioCryst Pharmaceuticals Inc	B	A	B	$9.83
KODKodiak Sciences Inc Common Stock	—	—	B	$39.46
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	B	$49.65
MESOMesoblast Limited American Depositary Shares	D	B	C	$17.19
VCELVericel Corporation	D	B	C	$43.22
ADMAADMA Biologics, Inc.	C	C	C	$9.72
TSHATaysha Gene Therapies, Inc. Common Stock	F	B	B	$6.20
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	$37.40
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	$3.56
VIRVir Biotechnology, Inc. Common Stock	B	B	B	$10.71
INBXInhibrx Biosciences, Inc. Common Stock	D	C	B	$122.72
ALVOAlvotech Ordinary Shares	C	D	B	$5.05
MAZEMaze Therapeutics, Inc. Common Stock	—	—	B	$30.42
NVAXNovavax Inc	B	D	C	$9.44
REPLReplimune Group, Inc.	—	—	A	$15.80
SLBTSL Science Holding Limited Ordinary Shares	—	—	F	$2.64
MGTXMeiraGTx Holdings plc Ordinary Shares	D	C	A	$14.92
VORVor Biopharma Inc. Common Stock	—	—	B	$24.01
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	A	$22.95
IMTXImmatics N.V. Ordinary Shares	C	D	C	$9.24
ODTXOdyssey Therapeutics, Inc. Common Stock	—	C	A	$26.23

About Dyadic International, Inc.

Dyadic International is a biotechnology company that develops and licenses a gene expression platform based on the C1 fungus (Thermothelomyces heterothallica) for producing industrial enzymes and proteins. The company generates recurring revenue through technology licensing agreements with major industrial partners including BASF, Abengoa Bioenergy, and Codexis for non-pharmaceutical applications.